The Current Ratio as of December 2024 (TTM) for Apellis Pharmaceuticals, Inc. (APLS) is 4.36

According to Apellis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.36. This represents a change of 6.94% compared to the average of 4.08 of the last 4 quarters.

Apellis Pharmaceuticals, Inc. (APLS) Historical Current Ratio (quarterly & annually)

How has APLS Current Ratio performed in the past?

The mean historical Current Ratio of Apellis Pharmaceuticals, Inc. over the last ten years is 9.87. The current 4.36 Current Ratio has changed 4.32% with respect to the historical average. Over the past ten years (40 quarters), APLS's Current Ratio was at its highest in in the December 2017 quarter at 27.77. The Current Ratio was at its lowest in in the March 2016 quarter at 0.

Apellis Pharmaceuticals, Inc. (APLS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Apellis Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Apellis Pharmaceuticals, Inc. (APLS) Average Current Ratio

How has APLS Current Ratio performed in the past?

The current Current Ratio of Apellis Pharmaceuticals, Inc. (APLS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Apellis Pharmaceuticals, Inc. (APLS) Current Ratio vs. Peers

How is APLS’s Current Ratio compared to its peers?

Apellis Pharmaceuticals, Inc.’s Current Ratio is less than Prometheus Biosciences, Inc. (31.04), less than Akero Therapeutics, Inc. (17.25), less than Immunovant, Inc. (7.61), less than Madrigal Pharmaceuticals, Inc. (5.98), less than Day One Biopharmaceuticals, Inc. (14.62), less than Mirati Therapeutics, Inc. (7.54), less than Amylyx Pharmaceuticals, Inc. (4.55), less than Terns Pharmaceuticals, Inc. (32.99), less than X4 Pharmaceuticals, Inc. (4.89), less than Inozyme Pharma, Inc. (7.68), less than Mereo BioPharma Group plc (6.10), greater than Blueprint Medicines Corporation (3.32), less than Cerevel Therapeutics Holdings, Inc. (10.22), less than Acumen Pharmaceuticals, Inc. (10.43),

Build a custom stock screener for Apellis Pharmaceuticals, Inc. (APLS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Apellis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Apellis Pharmaceuticals, Inc. (APLS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Apellis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.